Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARVINAS, INC.ARVN · Entity 5355 | Director | June 24, 2026 | June 26, 2026 |
| CENTENE CORPCNC · Entity 3133 | Director | March 31, 2022 | April 05, 2022 |
| CVS HEALTH CorpCVS · Entity 2884 | Director | May 14, 2026 | May 15, 2026 |
| ENDOLOGIX INC /DE/ELGX · Entity 146591 | Director | August 05, 2019 | August 06, 2019 |
| GLOBUS MEDICAL INCGMED · Entity 3496 | Director | January 21, 2026 | January 23, 2026 |
| ModivCare IncMODV · Entity 76927 | Director | February 14, 2024 | February 16, 2024 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | July 28, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARVINAS, INC.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,572 |
Reported balance
After 2026-06-24 transaction · row 1
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 15,527 · Balance 41,572 F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.05 · Expires 2036-06-23 | Direct | 22,714 |
Reported balance
After 2026-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-24 · Grant · Acquired 22,714 · Balance 22,714 F2: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.
F2: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.
CENTENE CORP
Report date March 31, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,481.005 |
Reported balance
After 2022-03-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-31 · Grant · Acquired 381.005 · Balance 1,481.005 F1: Ownership includes 1,100 shares of restricted stock units subject to vesting requirements. |
| Common Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $80.57 · Expires 2032-02-07 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2022-03-31 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Ownership includes 1,100 shares of restricted stock units subject to vesting requirements.
CVS HEALTH Corp
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,376 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 1,447 · Balance 7,376 F1: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.
ENDOLOGIX INC /DE/
Report date August 05, 2019 · Filed August 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,932 |
Reported balance
After 2019-08-05 transaction · row 1
1 source rowRow 1 · 2019-08-05 · Grant · Acquired 13,494 · Balance 29,932 F1: 100% of the time-based restricted stock unit award shall vest on August 5, 2020 and shall settle in shares of common stock. |
| Option to PurchaseSEC Table II · derivative / convertible security · Conversion / exercise price $6.67 · Expires 2029-08-05 | Direct | 9,023 |
Reported balance
After 2019-08-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-08-05 · Grant · Acquired 9,023 · Balance 9,023 F2: 100% of the option award shall vest on August 5, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the time-based restricted stock unit award shall vest on August 5, 2020 and shall settle in shares of common stock.
F2: 100% of the option award shall vest on August 5, 2020.
GLOBUS MEDICAL INC
Report date January 21, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy Class A Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $94.15 · Expires 2036-01-21 | Direct | 15,000 |
Reported balance
After 2026-01-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-21 · Grant · Acquired 15,000 · Balance 15,000 F1: These options were granted on January 21, 2026, and will vest on January 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted on January 21, 2026, and will vest on January 1, 2027.
ModivCare Inc
Report date February 14, 2024 · Filed February 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,830 |
Reported balance
After 2024-02-14 transaction · row 1
1 source rowRow 1 · 2024-02-14 · Grant · Acquired 2,658 · Balance 18,830 F1: Represents restricted shares scheduled to fully vest on February 14, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted shares scheduled to fully vest on February 14, 2025.
NEUROCRINE BIOSCIENCES INC
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,430 |
Ending reported balance
After 2026-07-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-28 · Sale · Disposed 1,250 · Balance 1,588 F1: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $182.00 to $182.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2026-07-29 · Exercise / conversion · Acquired 842 · Balance 2,430 |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $139.43 · Expires 2034-05-22 | Direct | 2,140 |
Reported balance
After 2026-07-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-29 · Exercise / conversion · Disposed 842 · Balance 2,140 F3: Option vested in 12 monthly installments beginning June 22, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $182.00 to $182.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Option vested in 12 monthly installments beginning June 22, 2024.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MAGELLAN HEALTH INC
Report date January 04, 2022 · Filed January 04, 2022
Section 16 reporting ended · disclosed 2022-01-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-01-04 transaction · row 1
1 source rowRow 1 · 2022-01-04 · Disposition to issuer · Disposed 5,698 · Balance 0 F1: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration"). F2: Includes 2,911 restricted shares of Common Stock. In accordance with the terms of the Merger Agreement, at the effective time of the Merger, each of these restricted shares of Common Stock was automatically cancelled and converted into the right to receive the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration").
F2: Includes 2,911 restricted shares of Common Stock. In accordance with the terms of the Merger Agreement, at the effective time of the Merger, each of these restricted shares of Common Stock was automatically cancelled and converted into the right to receive the Merger Consideration.
NUVASIVE INC
Report date September 01, 2023 · Filed September 05, 2023
Section 16 reporting ended · disclosed 2023-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 1
1 source rowRow 1 · 2023-09-01 · Disposition to issuer · Disposed 3,095 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares. |
| Restricted StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-01 · Disposition to issuer · Disposed 5,960 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-01 · Disposition to issuer · Disposed 3,725 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-01 · Disposition to issuer · Disposed 2,501 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-01 · Disposition to issuer · Disposed 2,822 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-01 · Disposition to issuer · Disposed 2,130 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-09-01 · Disposition to issuer · Disposed 3,230 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-09-01 · Disposition to issuer · Disposed 2,577 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-09-01 · Disposition to issuer · Disposed 2,702 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-09-01 · Disposition to issuer · Disposed 3,788 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-09-01 · Disposition to issuer · Disposed 4,816 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.
F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.
F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Press Ganey Holdings, Inc.
Report date October 21, 2016 · Filed October 25, 2016
Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-10-21 transaction · row 1
1 source rowRow 1 · 2016-10-21 · Disposition to issuer · Disposed 28,770 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2017 Filed Mar 15, 2017 21:45 UTC | ModivCare Inc PRSC · Entity 76927 | GrantCommon Stock | 3,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-004624 · rdgdoc.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,084 Read SEC document |
| October 21, 2016 Filed Oct 25, 2016 15:45 UTC | Press Ganey Holdings, Inc. PGND · Entity 181517 | Disposition to issuerCommon Stock | 28,770 | $40.50 | $1,165,185.00 |
DisclosureSEC source: 0001179110-16-030917 · edgar.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.